RPRX Company Profile and Key Details
Royalty Pharma plc
RPRX Stock Price Chart
Stock Price Today
Royalty Pharma plc (RPRX) stock declined over -0.56%, trading at $30.13 on NASDAQ, down from the previous close of $30.30. The stock opened at $30.08, fluctuating between $29.73 and $30.21 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Company Information
| Employees | 75 |
| Beta | 0.47 |
| Sales or Revenue | $2.35B |
| 5Y Sales Change% | 0.038% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Royalty Pharma plc (NASDAQ: RPRX) stock price is $30.13 in the last trading session. During the trading session, RPRX stock reached the peak price of $30.21 while $29.73 was the lowest point it dropped to. The percentage change in RPRX stock occurred in the recent session was -0.56% while the dollar amount for the price change in RPRX stock was -$0.17.
The NASDAQ listed RPRX is part of Biotechnology industry that operates in the broader Healthcare sector. Royalty Pharma plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. George Grofik C.F.A., C.P.A.
Senior Vice President and Head of Investor Relations & Communications
Ms. Alessandra Sassun
Senior Vice President & Head of Human Capital
Mr. Arthur R. McGivern J.D.
Executive Vice President of Investments & Gen. Counsel
Mr. Ashwin Pai M.D.
Executive Vice President of Investments
Ms. Kristin Stafford
Senior Vice President & Chief Accounting Officer
Dr. James Folmar Reddoch Ph.D.
Executive Vice President of Investments & Chief Scientific Officer
Mr. George Grofik C.F.A., CPA
Senior Vice President and Head of Investor Relations & Communications
Mr. Pablo Gerardo Legorreta
Founder, Chairman & Chief Executive Officer
Mr. Terrance P. Coyne
Executive Vice President & Chief Financial Officer
Mr. George Wingate Lloyd
Executive Vice President of Investments & Chief Legal Officer
Mr. Christopher Hite
Vice Chairman & Executive Vice President
Dr. Marshall Urist M.D., Ph.D.
Executive Vice President and Head of Research & Investments
RPRX's closing price is 25.99% higher than its 52-week low of $24.05 where as its distance from 52-week high of $31.66 is -4.28%.
Number of RPRX employees currently stands at 75.
Official Website of RPRX is: https://www.royaltypharma.com
RPRX could be contacted at phone 212 883 0200 and can also be accessed through its website. RPRX operates from 110 East 59th Street, New York, NY 10022, United States.
RPRX stock volume for the day was 2.1M shares. The average number of RPRX shares traded daily for last 3 months was 3.23M.
The market value of RPRX currently stands at $13.39B with its latest stock price at $30.13 and 444.3M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com